CIK 0001582554 · Non-accelerated filer<br>Smaller reporting company
Matinas BioPharma Holdings, Inc.
Sign in to watch- Ticker
- MTNB
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463011414
- Phone
- 908-484-8805
- Business address
- 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER, NJ, 07921
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-04-30 | NEUGEBOREN EDWARD Director | Grant or award · Stock Option (right to Buy) | +11,600 | 11,600 | ||
| 2025-04-30 | Murphy Keith Director | Grant or award · Stock Option (right to Buy) | +11,600 | 11,600 | ||
| 2025-04-30 | Jabbour Jerome D President and CEO | Grant or award · Stock Option (right to Buy) | +70,100 | 70,100 | ||
| 2025-04-30 | D An Evelyn Director | Grant or award · Stock Option (right to Buy) | +11,600 | 11,600 | ||
| 2025-04-08 | Sanitam Partners LLC 10% owner | Purchase · Series C Convertible Preferred Stock | +703 | $1,000.00 | $703K | 1,406 |
| 2025-04-08 | Sanitam Partners LLC 10% owner | Purchase · Warrants | +2,399,318 | 4,798,636 | ||
| 2025-04-08 | EIDE ROBERT J 10% owner | Purchase · Series C Convertible Preferred Stock | +492 | $1,000.00 | $492K | 984 |
| 2025-04-08 | EIDE ROBERT J 10% owner | Purchase · Warrants | +1,679,182 | 3,358,364 | ||
| 2025-04-08 | Pembroke & Partners LLC 10% owner | Purchase · Series C Convertible Preferred Stock | +492 | $1,000.00 | $492K | 984 |
| 2025-04-08 | Pembroke & Partners LLC 10% owner | Purchase · Warrants | +1,679,182 | 3,358,364 | ||
| 2023-12-15 | Liu Hui Chief Technology Officer | Grant or award · Stock Option (right to Buy) | +1,000,000 | 1,000,000 | ||
| 2023-12-15 | Kucinski Keith A Chief Financial Officer | Grant or award · Stock Option (right to Buy) | +1,000,000 | 1,000,000 | ||
| 2023-12-15 | Jabbour Jerome D President and CEO | Grant or award · Stock Option (right to Buy) | +3,500,000 | 3,500,000 | ||
| 2023-12-15 | Hoover Thomas Chief Business Officer | Grant or award · Stock Option (right to Buy) | +1,000,000 | 1,000,000 | ||
| 2023-12-15 | Ferguson James J. III Chief Medical Officer | Grant or award · Stock Option (right to Buy) | +1,200,000 | 1,200,000 | ||
| 2023-12-15 | Matkovits Theresa Chief Development Officer | Grant or award · Stock Option (right to Buy) | +1,300,000 | 1,300,000 | ||
| 2023-11-01 | Giordano Natasha Director | Grant or award · Stock option (right to buy) | +437,244 | 437,244 | ||
| 2023-11-01 | WIKLER MATTHEW Director | Grant or award · Stock option (right to buy) | +437,244 | 437,244 | ||
| 2023-11-01 | Corzo Kathryn Penkus Director | Grant or award · Stock option (right to buy) | +437,244 | 437,244 | ||
| 2023-11-01 | Scibetta James S Director | Grant or award · Stock option (right to buy) | +437,244 | 437,244 |
Page 2 of 14 · 264 trades